Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial

Journal of Clinical Oncology

Volumn 18, Issue 22, 2000, Pages 3758-3767

  Nabholtz, J M ^a   Buzdar, A ^a   Pollak, M ^a   Harwin, W ^a   Burton, G ^a   Mangalik, A ^a   Steinberg, M ^a   Webster, A ^a   Von Euler, M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NORTH AMERICA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; VAGINA BLEEDING;

EID: 0034669484     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.22.3758     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials
2. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
3. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
4. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials
5. Use of tamoxifen for breast cancer: Twenty-eight years later
6. Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications
7. Aromatase inhibitors
8. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma
9. Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen
10. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
11. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
12. First-line fadrozole HCL (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomised trial of the Swiss Group for Clinical Cancer Res SAKK 20/88
13. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
14. Neoadjuvant treatment with anastrazole (Arimidex) causes profound suppression of intratumor estrogen levels
15. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
16. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability) Study
17. Assessment of response to therapy in advanced breast cancer
18. Clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer
19. Static disease on anastrozole provides similar benefits as objective response in patients with advanced breast cancer
20. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
21. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy
22. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
23. Cytotoxic and hormonal treatment for metastatic breast cancer. A systematic review of published randomized trials involving 31,510 women
24. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer
25. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients
26. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - A phase III trial of the Piedmont Oncology Association
27. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer
28. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer
29. A randomized phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer
30. Oral high-dose medroxyprogesterone acetate versus tamoxifen: A randomized cross-over trial in postmenopausal patients with advanced breast cancer
31. Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate?
32. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study
33. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
34. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: A Southeastern Cancer Study Group trial
35. Hormonal treatment of advanced breast cancer: A randomized trial of tamoxifen versus nandrolone decanoate
36. Tamoxifen and fluoxymesterone in advanced breast cancer: A controlled clinical trial
37. Toremifen and tamoxifen in advanced breast cancer: A double-blind cross-over trial
38. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two Phase III trials
39. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
40. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma
41. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer